Hepatic angiomyolipoma （HAML） is a rare benign mesenchymal tumor frequently observed in middle-aged women. Due to the absence of prominent symptoms in the early stage and the lack of specific imaging findings， the diagnosis of this disease can be challenging， leading to a high rate of misdiagnosis. This article reports a case of giant HAML with subcapsular rupture that was misdiagnosed as hepatocellular carcinoma and introduces the characteristics of the case and its diagnosis and treatment process， in order to provide a reference for the diagnosis and treatment of this type of disease.

Resistance to ferroptosis, a form of regulated cell death caused by disruptions in iron ion and intracellular redox homeostasis, is closely related to tumorigenesis and tumor drug resistance; therefore, targeting ferroptosis-related pathways has garnered attention as a potential antitumor therapeutic strategy. However, the molecular mechanisms underlying ferroptosis resistance in tumor cells remain unknown. Zinc-finger estrogen receptor interaction clone 6 (ZER6) consists of two isoforms with distinct N-termini, p52-ZER6 and p71-ZER6. ZER6 is upregulated in tumors and promotes tumorigenic potential; however, whether ZER6 is involved in tumor cell ferroptosis resistance remains unknown. Herein, we identified p52-ZER6 as a novel regulator of tumor cell ferroptosis resistance. p52-ZER6 promotes the transcriptional activity of DAZAP1, an RNA-binding protein. DAZAP1, in turn, enhances the stability of SLC7A11 mRNA by binding to its 3'-UTR region, thereby increasing SLC7A11 expression and cellular glutathione levels. This subsequently reduces lipid peroxide accumulation and enhances tumor cell ferroptosis resistance, eventually promoting tumorigenic potential. These findings reveal a new function of p52-ZER6 in regulating SLC7A11 mRNA stability via DAZAP1, ultimately leading to ferroptosis resistance and tumorigenic potential. Additionally, we also suggest targeting p52-ZER6 as a potential strategy to promote the efficacy of ferroptosis-based antitumor therapies.

Objective:To explore the effects of novel coronaviral infection on the outcomes of liver transplantation recipients.Methods:The relevant clinical data were retrospectively reviewed for 5 liver transplantation recipients infected with novel coronavirus during perioperative period at First Hospital of Shanxi Medical University.At the same time, "liver transplantation" and "novel coronavirus" and "2019 novel coronavirus" or "SARS-CoV-2" were employed as Chinese and English keywords respectively for searching the relevant literature items of CNKI, Wanfang and PubMed from the inception of database until February 2023.The impact of perioperative novel coronaviral infection was examined on the outcomes of liver transplantation recipients.Results:From November 2022 to January 2023, liver transplantation was performed in 5 recipients of donated liver after death.Two cases tested positive for real-time polymerase chain reaction(RT-PCR)at Day 14/20 pre-operation and converted into negative post-operation.Three cases were infected with SARS-CoV-2 at Day 1/10/16 post-operation.And one of them became feverish again at Day 11 post-infection.With a peak temperature of 39.5 degrees, it rapidly progressed into multiple organ failures of heart, lung and kidney.After active interventions, organ function gradually recovered.Through literature searches, 9 eligible English literature items were retrieved.However, there was no Chinese entry.Among 15 liver transplantation recipients with SARS-CoV-2 infection, one died from septic shock, another from graft failure and the remainders survived.Conclusions:liver transplantation recipients infected with SARS-CoV-2 and negative RT-PCR pre-operation are asymptomatic.Without signs of pneumonia on chest CT, transplantation may be performed.For post-liver transplantation recipients with early SARS-CoV-2 infection, close monitoring of important organ functions such as heart, lung, liver and kidney, timely antiviral regimen and tapered use of immunosuppression can achieve a decent prognosis.

Liver diseases are common in China and the incidence and mortality of primary liver cancer are among the top in the world. As one of the therapeutic methods for hepatocellular carcinoma (HCC), liver transplantation has become an important technique in hepatic surgery. Most of patients with HCC have progressed to stage B or C of Barcelona Clinic Liver Cancer staging when diagnosed. How to reduce the dropout rate of HCC patients due to the progression of tumor when waiting for liver transplantation, develop individualized immunosuppressant plans for HCC patients after liver transplantation, and accurately manage patients with HCC recurrence after liver transplan-tation are the current hotspots of research. The authors review the relevant literature, summarize the treatment experience, and discuss the hot issues in liver transplantation for HCC, in order to provide reference for related treatment.